EA
SUPN icon

Ellsworth Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Ellsworth Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$836K Buy
17,520
+678
+4% +$32.6K 0.14% 129
2026
Q1 		$871K Buy
+16,842
New +$858K 0.16% 110

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Ellsworth Advisors's SUPN Position: Q2 2026 in Review

Ellsworth Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 4% in Q2 2026, buying an estimated $32.6K and bringing the position to 17,520 shares worth $836K. The position accounts for 0.14% of the portfolio, ranked #129.

Ellsworth Advisors first reported a position in SUPN in Q1 2026 and has held it in 2 quarters since. The position peaked at $871K in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Ellsworth Advisors held 17,520 shares of Supernus Pharmaceuticals worth $836K as of Q2 2026.
  • Ellsworth Advisors bought 678 Supernus Pharmaceuticals shares in Q2 2026, an estimated $32.6K.
  • Supernus Pharmaceuticals made up 0.14% of Ellsworth Advisors's portfolio in Q2 2026, its #129 holding.
  • Ellsworth Advisors first reported a position in Supernus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Ellsworth Advisors's Supernus Pharmaceuticals position peaked at $871K in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.